FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3080422972> ?p ?o ?g. }

• W3080422972 endingPage "81.e2" @default.
• W3080422972 startingPage "74" @default.
• W3080422972 abstract "Objective To evaluate umbilical cord messenger RNA (mRNA) expression as biomarkers for the grade of hypoxic-ischemic encephalopathy (HIE) and long-term neurodevelopment outcome. Study design Infants were recruited from the BiHiVE1 study, Ireland (2009-2011), and the BiHiVE2 study, Ireland, and Sweden (2013-2015). Infants with HIE were assigned modified Sarnat scores at 24 hours and followed at 18-36 months. mRNA expression from cord blood was measured using quantitative real-time polymerase chain reaction. Results We studied 124 infants (controls, n = 37; perinatal asphyxia, n = 43; and HIE, n = 44). Fzd4 mRNA increased in severe HIE (median relative quantification, 2.98; IQR, 2.23-3.68) vs mild HIE (0.88; IQR, 0.46-1.37; P = .004), and in severe HIE vs moderate HIE (1.06; IQR, 0.81-1.20; P = .003). Fzd4 mRNA also increased in infants eligible for therapeutic hypothermia (1.20; IQR, 0.92-2.37) vs those who were ineligible for therapeutic hypothermia group (0.81; IQR, 0.46-1.53; P = .017). Neurodevelopmental outcome was analyzed for 56 infants. Nfat5 mRNA increased in infants with severely abnormal (1.26; IQR, 1.17-1.39) vs normal outcomes (0.97; IQR, 0.83-1.24; P = .036), and also in infants with severely abnormal vs mildly abnormal outcomes (0.96; IQR, 0.80-1.06; P = .013). Fzd4 mRNA increased in infants with severely abnormal (2.51; IQR, 1.60-3.56) vs normal outcomes (0.74; IQR, 0.48-1.49; P = .004) and in infants with severely abnormal vs mildly abnormal outcomes (0.97; IQR, 0.75-1.34; P = .026). Conclusions Increased Fzd4 mRNA expression was observed in cord blood of infants with severe HIE; Nfat5 mRNA and Fzd4 mRNA expression were increased in infants with severely abnormal long-term outcomes. These mRNA may augment current measures as early objective markers of HIE severity at delivery. To evaluate umbilical cord messenger RNA (mRNA) expression as biomarkers for the grade of hypoxic-ischemic encephalopathy (HIE) and long-term neurodevelopment outcome. Infants were recruited from the BiHiVE1 study, Ireland (2009-2011), and the BiHiVE2 study, Ireland, and Sweden (2013-2015). Infants with HIE were assigned modified Sarnat scores at 24 hours and followed at 18-36 months. mRNA expression from cord blood was measured using quantitative real-time polymerase chain reaction. We studied 124 infants (controls, n = 37; perinatal asphyxia, n = 43; and HIE, n = 44). Fzd4 mRNA increased in severe HIE (median relative quantification, 2.98; IQR, 2.23-3.68) vs mild HIE (0.88; IQR, 0.46-1.37; P = .004), and in severe HIE vs moderate HIE (1.06; IQR, 0.81-1.20; P = .003). Fzd4 mRNA also increased in infants eligible for therapeutic hypothermia (1.20; IQR, 0.92-2.37) vs those who were ineligible for therapeutic hypothermia group (0.81; IQR, 0.46-1.53; P = .017). Neurodevelopmental outcome was analyzed for 56 infants. Nfat5 mRNA increased in infants with severely abnormal (1.26; IQR, 1.17-1.39) vs normal outcomes (0.97; IQR, 0.83-1.24; P = .036), and also in infants with severely abnormal vs mildly abnormal outcomes (0.96; IQR, 0.80-1.06; P = .013). Fzd4 mRNA increased in infants with severely abnormal (2.51; IQR, 1.60-3.56) vs normal outcomes (0.74; IQR, 0.48-1.49; P = .004) and in infants with severely abnormal vs mildly abnormal outcomes (0.97; IQR, 0.75-1.34; P = .026). Increased Fzd4 mRNA expression was observed in cord blood of infants with severe HIE; Nfat5 mRNA and Fzd4 mRNA expression were increased in infants with severely abnormal long-term outcomes. These mRNA may augment current measures as early objective markers of HIE severity at delivery." @default.
• W3080422972 created "2020-09-01" @default.
• W3080422972 creator A5002852091 @default.
• W3080422972 creator A5003021083 @default.
• W3080422972 creator A5007205193 @default.
• W3080422972 creator A5011863590 @default.
• W3080422972 creator A5019262839 @default.
• W3080422972 creator A5025263935 @default.
• W3080422972 creator A5079129373 @default.
• W3080422972 creator A5084014715 @default.
• W3080422972 date "2021-01-01" @default.
• W3080422972 modified "2023-10-12" @default.
• W3080422972 title "Up-Regulation of Nfat5 mRNA and Fzd4 mRNA as a Marker of Poor Outcome in Neonatal Hypoxic-Ischemic Encephalopathy" @default.
• W3080422972 cites W1549826613 @default.
• W3080422972 cites W1550814098 @default.
• W3080422972 cites W1964232672 @default.
• W3080422972 cites W1977789763 @default.
• W3080422972 cites W1985230697 @default.
• W3080422972 cites W1992659047 @default.
• W3080422972 cites W1995665812 @default.
• W3080422972 cites W1997309506 @default.
• W3080422972 cites W2014086693 @default.
• W3080422972 cites W2016497346 @default.
• W3080422972 cites W2016619395 @default.
• W3080422972 cites W2016962985 @default.
• W3080422972 cites W2031522329 @default.
• W3080422972 cites W2036178413 @default.
• W3080422972 cites W2041935553 @default.
• W3080422972 cites W2048203988 @default.
• W3080422972 cites W2055313665 @default.
• W3080422972 cites W2059767791 @default.
• W3080422972 cites W2060985684 @default.
• W3080422972 cites W2068074059 @default.
• W3080422972 cites W2076852872 @default.
• W3080422972 cites W2088727502 @default.
• W3080422972 cites W2094358667 @default.
• W3080422972 cites W2096981766 @default.
• W3080422972 cites W2105788666 @default.
• W3080422972 cites W2109476525 @default.
• W3080422972 cites W2112187582 @default.
• W3080422972 cites W2112251186 @default.
• W3080422972 cites W2112963538 @default.
• W3080422972 cites W2114570899 @default.
• W3080422972 cites W2116178187 @default.
• W3080422972 cites W2119043140 @default.
• W3080422972 cites W2125411036 @default.
• W3080422972 cites W2136875315 @default.
• W3080422972 cites W2144987360 @default.
• W3080422972 cites W2146619649 @default.
• W3080422972 cites W2153032620 @default.
• W3080422972 cites W2154266727 @default.
• W3080422972 cites W2155688961 @default.
• W3080422972 cites W2156246479 @default.
• W3080422972 cites W2158021558 @default.
• W3080422972 cites W2159473136 @default.
• W3080422972 cites W2168630917 @default.
• W3080422972 cites W2169597792 @default.
• W3080422972 cites W2556227869 @default.
• W3080422972 cites W2603009846 @default.
• W3080422972 cites W2898668651 @default.
• W3080422972 cites W2907935749 @default.
• W3080422972 doi "https://doi.org/10.1016/j.jpeds.2020.08.051" @default.
• W3080422972 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32828883" @default.
• W3080422972 hasPublicationYear "2021" @default.
• W3080422972 type Work @default.
• W3080422972 sameAs 3080422972 @default.
• W3080422972 citedByCount "5" @default.
• W3080422972 countsByYear W30804229722021 @default.
• W3080422972 countsByYear W30804229722022 @default.
• W3080422972 countsByYear W30804229722023 @default.
• W3080422972 crossrefType "journal-article" @default.
• W3080422972 hasAuthorship W3080422972A5002852091 @default.
• W3080422972 hasAuthorship W3080422972A5003021083 @default.
• W3080422972 hasAuthorship W3080422972A5007205193 @default.
• W3080422972 hasAuthorship W3080422972A5011863590 @default.
• W3080422972 hasAuthorship W3080422972A5019262839 @default.
• W3080422972 hasAuthorship W3080422972A5025263935 @default.
• W3080422972 hasAuthorship W3080422972A5079129373 @default.
• W3080422972 hasAuthorship W3080422972A5084014715 @default.
• W3080422972 hasConcept C126322002 @default.
• W3080422972 hasConcept C187212893 @default.
• W3080422972 hasConcept C2777390192 @default.
• W3080422972 hasConcept C2778080812 @default.
• W3080422972 hasConcept C2778621155 @default.
• W3080422972 hasConcept C2779914510 @default.
• W3080422972 hasConcept C2780164069 @default.
• W3080422972 hasConcept C2909832856 @default.
• W3080422972 hasConcept C71924100 @default.
• W3080422972 hasConcept C90924648 @default.
• W3080422972 hasConceptScore W3080422972C126322002 @default.
• W3080422972 hasConceptScore W3080422972C187212893 @default.
• W3080422972 hasConceptScore W3080422972C2777390192 @default.
• W3080422972 hasConceptScore W3080422972C2778080812 @default.
• W3080422972 hasConceptScore W3080422972C2778621155 @default.
• W3080422972 hasConceptScore W3080422972C2779914510 @default.
• W3080422972 hasConceptScore W3080422972C2780164069 @default.
• W3080422972 hasConceptScore W3080422972C2909832856 @default.
• W3080422972 hasConceptScore W3080422972C71924100 @default.

• next